Indian Journal of Dermatology
RESIDENTS PAGE
Year
: 2016  |  Volume : 61  |  Issue : 2  |  Page : 181--186

Approach to infantile hemangiomas


Anil Abraham, Anupa Mary Job, Gillian Roga 
 Department of Dermatology, St. John's Medical College Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Anil Abraham
Department of Dermatology, St. John's Medical College Hospital, Sarjapur Road, Bengaluru - 560 034, Karnataka
India

Abstract

Infantile hemangiomas are a group of vascular tumors and are considered to be one of the most common tumors in infancy. Ambiguity still prevails over its origin, etiopathogenesis, and optimal management.



How to cite this article:
Abraham A, Job AM, Roga G. Approach to infantile hemangiomas.Indian J Dermatol 2016;61:181-186


How to cite this URL:
Abraham A, Job AM, Roga G. Approach to infantile hemangiomas. Indian J Dermatol [serial online] 2016 [cited 2021 Nov 28 ];61:181-186
Available from: https://www.e-ijd.org/text.asp?2016/61/2/181/177755


Full Text

 Introduction



Vascular anomalies have been classified as vascular tumors and malformations, a modification to the original classification system by Finn et al. in 1982,[1] by the International Society for the Study of Vascular Anomalies in 1996.[2] Infantile hemangioma (IH), grouped under vascular tumors, has a prevalence of 1.1–2.6% in term neonates as evidenced from the world literature and a 0.1–0.28% as recorded in Indian literature.[3] It derives its name from a Latin word “Hemangioma fructosum.” Although considered to be the most common tumor in infancy, ambiguity still prevails over its origin, etiopathogenesis, and optimal management.

Etiopathogenesis

IH pathogenesis is considered to be a complex interaction of both genetic and environmental factors. A closer look at clinical characteristics, including the marked clinical heterogeneity, the significance of premonitory marks, growth and involution characteristics, anatomic patterns, presence only in certain tissues, multifocal hemangiomas, and associated structural anomalies may all provide clues to the pathogenesis of IH.[4] Over the last decade, several theories have been proposed, of which Folkman Klagsbrun placental theory, endothelial progenitor cell theory, hypoxia theory, and angiogenesis theory are the most accepted.[5],[6],[7],[8],[9]

Clinical features

The risk factors and higher incidence of the development of IH are prematurity, multiple gestation, elderly primigravida, and placental abnormalities such as placenta previa and preeclampsia. It is more common in white infants (10%), with a higher female preponderance (3:1). The natural history of IH can be studied based on the clinical stage of the condition [Table 1].[9],[10] These features help to differentiate it from its closest differential diagnosis of congenital hemangiomas, which are fully developed at birth with no postnatal growth. IH can be classified based on its depth and extent of involvement [Table 2].[4],[10]{Table 1}{Table 2}

Complications of infantile hemangiomas

Morbidity and mortality resulting from IH are varied, ranging from life-threatening complications such as bleeding, airway obstruction mainly occurring during the proliferative phase to scarring and disfigurement seen predominantly in the involution phase. Various complications encountered in clinical practice have been discussed in [Table 3].[8],[9],[10],[11],[12],[13]{Table 3}

 Diagnosis



IH is usually diagnosed based on history and examination. Investigations are deemed appropriate in case of doubtful cases (e.g., to differentiate deep IH and vascular malformations) or in case of suspected associated systemic abnormalities (e.g., large facial segmental plaque-like hemangiomas can be associated with posterior fossa malformations–hemangiomas–arterial anomalies–cardiac defects–eye abnormalities–sternal cleft and supraumbilical raphe [PHACES] syndrome).[12]

Line of work up for large facial hemangiomas includes an ultrasound (US) of the head in infants <4 months of age and magnetic resonance imaging (MRI) with angiography for those >4 months of age. In case of detected central nervous system abnormalities, a repeat MRI once every 3 months until 18 months of age is recommended. USG of an IH lesion can help rule out a close differential diagnosis of vascular malformations. Characteristic findings in US include well-defined hypoechoic, heterogeneous texture with cystic sinusoidal spaces, and fast flow pattern. Further, infants with >5 IH lesions warrant a hepatic US considering the possibility of hepatic hemangiomas. Minority of these can be multifocal liver hemangiomas, which can result in high output cardiac failure. A rarer form, diffuse hepatic hemangiomas can cause abdominal compartment syndrome and a severe form of hypothyroidism.[13] MRI can be used to confirm the extent and tissue characteristics of IH lesions. Typical features in the proliferating phase include dilated feeding vessels, variable intensity T1, hyperintense T2, and flow voids around and within the mass. In the involuted phase, decrease in vessel size is seen.[14] The various imaging modalities in special situations have been described briefly in [Table 4].{Table 4}

Biopsy can be considered in case of lesions with unclear etiology, unusual appearances, and atypical features. Early proliferating lesions display solid cellular lobules composed of plump endothelial cells lining tiny rounded vascular spaces with inconspicuous lumina.[12] Regressed lesions show progressive fibrosis, absent vascular elements, and fat replacement of vascular tissue in the subcutaneous layer. The expression of glucose transporters-1 only in IH endothelium helps confirm the diagnosis.

Recently, urinary basic fibroblast growth factor and vascular endothelial growth factor estimation have been found to be reliable markers in IH proliferation and differentiation.[13]

Treatment

The “Guidelines of care for hemangiomas of infancy” published in the Journal of the American Academy of Dermatology,[14] defines the major goals of the management of IH as:

Prevention or reversal of life-threatening or function-threatening complications Prevention of permanent disfigurement, diminution of psychosocial stress for the patient and family Avoidance of aggressive or detrimental interventions in lesions that may have excellent prognosis without treatment Prevention or treatment of ulceration to lower scarring, infection, and pain.

Most cases of IH are self-limited and require no active intervention. The indication for treatment and how best to administer the same depends on the clinical situation and must take into consideration the factors such as age of the patient, location of lesions, complications, and risks for the same, and growth rate of the lesions [Table 5].[9],[13],[14] An “active nonintervention” approach suffices in most cases of uncomplicated IH [Table 6].[13],[14]{Table 5}{Table 6}

A Cochrane analysis of interventions for IH noted that a lack of well-designed clinical trials and the absence of US Food and Drug Administration-approved medications for IH limits the ability to clearly identify a single best treatment option for IHs.[15]

Until recently, systemic and intralesional corticosteroids were the mainstay of management of complicated hemangiomas. However, at present, beta-blockers, in particular, propranolol has come up as the first line of management of IH [Table 7] and [Table 8].[4],[16],[17],[18],[19] Various other modalities can be tried in clinical practice for managing IH [Table 9].[18],[19],[20],[21],[22],[23],[24]{Table 7}{Table 8}{Table 9}

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: Clinical application of a new classification. J Pediatr Surg 1983;18:894-900.
2Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997;13:375-423.
3Mendiratta V, Jabeen M. Infantile hemangioma: An update. Indian J Dermatol Venereol Leprol 2010;76:469-75.
4Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005;22:383-406.
5Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: An update on pathogenesis and therapy. Pediatrics 2013;131:99-108.
6North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000;31:11-22.
7Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: Does hypoxia connect the dots? Arch Dermatol 2010;146:1295-9.
8Holland KE, Drolet BA. Approach to the patient with an infantile hemangioma. Dermatol Clin 2013;31:289-301.
9Hajheydari Z, Shahmohammadi S, Talaee R. Update on infantile haemangioma. J Pediatr Rev 2014;2:29-38.
10Wong A, Wu JK. Infantile Hemangiomas: A Disease Model in the Study of Vascular Development, Aberrant Vasculogenesis and Angiogenesis, Tumor Angiogenesis, Dr. Sophia Ran (Ed.), ISBN: 978-953-51-0009-6.2012. InTech, Available from: http://www.intechopen.com/books/tumor-angiogenesis/infantilehemangiomas-a-disease-model-in-the-study-of-vascular-development-aberrant-vasculogenesis-a. [Last accessed on 2015 Feb 24].
11Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol 1960;82:667-80.
12Callahan AB, Yoon MK. Infantile hemangiomas: A review. Saudi J Ophthalmol 2012;26:283-91.
13Zhang L, Lin X, Wang W, Zhuang X, Dong J, Qi Z, et al. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 2005;116:200-4.
14Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997;37:631-7.
15Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882-7.
16Kum JJ, Khan ZA. Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis. Pediatr Res 2014;75:381-8.
17Sethuraman G, Yenamandra VK, Gupta V. Management of infantile hemangiomas: Current trends. J Cutan Aesthet Surg 2014;7:75-85.
18Greinwald JH Jr., Burke DK, Bonthius DJ, Bauman NM, Smith RJ. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999;125:21-7.
19Gunturi N, Ramgopal S, Balagopal S, Scott JX. Propranolol therapy for infantile hemangioma. Indian Pediatr 2013;50:307-13.
20Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg 1994;33:46-51.
21Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: Treatment of superficial vs mixed hemangiomas. Arch Dermatol 2000;136:628-32.
22Grover C, Khurana A, Bhattacharya SN. Sclerotherapy for the treatment of infantile hemangiomas. J Cutan Aesthet Surg 2012;5:201-3.
23Mascarenhas R, Guiote V, Agro J, Henrique M. Ulcerated infantile hemangioma treated with imiquimod. Dermatol Online J 2011;17:13.
24Nomura T, Osaki T, Ishinagi H, Ejiri H, Terashi H. Simple and easy surgical technique for infantile hemangiomas: Intralesional excision and primary closure. Eplasty 2015;15:e3.